|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||51.25 - 51.25|
|52 Week Range||36.26 - 56.34|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||320.31|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.86|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
MORRISVILLE, N.C., Aug. 13, 2019 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
Syneos Health (SYNH) delivered earnings and revenue surprises of 5.71% and 1.60%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Highlights GAAP revenue of $1,166.8 million for the three months ended June 30, 2019, representing growth of 8.8% compared to the same period in 2018.Adjusted revenue of.
Highlighted in the Commanders and Chiefs category, PharmaVOICE recognizes Alistair as a transformative leader, creating and deploying an industry-changing business model that provides biopharmaceutical customers with a better, faster way to bring therapies to patients. As CEO of the industry’s first biopharma accelerator, in 2017, Alistair led the merger of INC Research and inVentiv Health, to create Syneos Health, combining a leading Contract Research Organization (CRO) and the industry’s largest Contract Commercial Organization (CCO).
Syneos Health (SYNH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TORONTO, July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men's Health experience to capture a significant share of the U.S. market for NATESTO®. Under the terms of the new agreement, Aytu returns the NDA for NATESTO® in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies' joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel).
How far off is Syneos Health, Inc. (NASDAQ:SYNH) from its intrinsic value? Using the most recent financial data, we'll...
MORRISVILLE, N.C., July 08, 2019 -- Syneos HealthTM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research.
Read the beginning of this article here. The most valuable position in Hawk Ridge Capital Management’s 13F portfolio was in frontdoor, inc. (NASDAQ:FTDR) worth $31.04 million, counting 901,855 shares, amassing 6.54% of its equity portfolio. Frontdoor is one of the biggest US providers of home service plans with a large network of pre-qualified contractors. It […]
Low-cost index funds make it easy to achieve average market returns. But across the board there are plenty of stocks...
MORRISVILLE, N.C., June 24, 2019 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today introduced FSP 360, an evolved FSP.
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
Syneos Health Inc NASDAQ/NGS:SYNHView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SYNH with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SYNH totaled $324 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.